Matthew T Campbell, MD, MS
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2015 | University of Texas MD Anderson Cancer Center, Houston, TX, USA, MS, Biomedical Science |
| 2007 | Indiana University School of Medicine, Indianapolis, IN, USA, MD, Medicine |
| 2003 | DePauw University, Greencastle, IN, USA, BA, Chemistry |
Postgraduate Training
| 2012-2015 | Clinical Fellowship, Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX |
| 2008-2011 | Clinical Residency, Internal Medicine, Indiana University School of Medicine, Indianapolis, IN |
| 2007-2008 | Basic Science Research Laboratory Assistant, Pediatric Urology, Indiana University School of Medicine, Indianapolis, IN |
Board Certifications
| 2015 | American Board Medical Oncology |
| 2011 | American Board of Internal Medicine |
Experience & Service
Academic Appointments
Fellow, Department of Genitourinary Medical Oncology, Division of Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2015
Intern, Division of Internal Medicine, Indiana University School of Medicine, Department of Internal Medicine, Indianapolis, IN, 2008 - 2011
Administrative Appointments/Responsibilities
Liaison, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - Present
Co-Director, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - Present
Other Appointments/Responsibilities
Chief Fellow - Hematology/Medical Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2015
Chief Resident, Indiana University School of Medicine, Department of Internal Medicine-VA Roudebush Hospital, Indianapolis, IN, 2011 - 2012
Basic Science Laboratory Assistant, Indiana University School of Medicine, Department of Pediatric Urology, Indianapolis, IN, 2007 - 2008
Institutional Committee Activities
Committee Member, Clinical Research Committee (CRC) in Department of Clinical Cancer Prevention, 2016 - Present
Co-Chair, Adrenal Research Clinical Trials, 2016 - Present
Committee Member, Model of Care Workgroup, 2016 - Present
Committee Member, Renal Cell Carcinoma Research & Protocol, 2016 - Present
Honors & Awards
| 2018 | Teaching Department of the Year, The University of Texas MD Anderson Cancer Center - Hematology/Oncology Fellowship Program |
| 2018 | Teacher of the Year, The University of Texas MD Anderson Cancer Center - Hematology/Oncology Fellowship Program |
| 2017 | Teaching Department of the Year, The University of Texas MD Anderson Cancer Center - Hematology/Oncology Fellowship Program |
| 2015 | Humanitas Award for Compassionate Care of Patients, UT MD Anderson Cancer Center |
| 2013 | Clifton D. Howe Award for Clinical Excellence, UT MD Anderson Cancer Center |
| 2001 | Percy L. Julian, DePauw University |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT,, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 380(12):1103-1115, 2019. e-Pub 2019. PMID: 30779531.
- Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT,, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 25(1):188, 2019. e-Pub 2018. PMID: 30479380.
- Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT,, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 24(12):1804-1808, 2018. e-Pub 2018. PMID: 30420754.
- Campbell MT,, Bilen MA, Shah AY, Lemke E, Jonasch E, Venkatesan AM, Altinmakas E, Duran C, Msaouel P, Tannir NM. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. Eur J Cancer 104:188-194, 2018. e-Pub 2018. PMID: 30380460.
- Özdemir BC, Siefker-Radtke AO, Campbell MT,, Subudhi SK. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. Eur Urol Focus 4(3):442-454, 2018. e-Pub 2017. PMID: 29056275.
- Campbell MT,, Shah AY, Matin SF, Siefker-Radtke AO. Optimizing management of upper tract urothelial carcinoma. Urol Oncol 35(7):492-498, 2017. e-Pub 2017. PMID: 28579283.
- Siefker-Radtke AO, Campbell MT,. Reply to B. Biswas et al. J Clin Oncol 35(18):JCO2017732644, 2017. e-Pub 2017. PMID: 28471712.
- Matrana MR, Baiomy A, Campbell MT,, Alamri S, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Elsayes KM, Tannir NM. Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib. Clin Genitourin Cancer 15(2):e205-e208, 2017. e-Pub 2016. PMID: 27568124.
- Siefker-Radtke AO, Campbell MT,. Now Is the Time for Perioperative Chemotherapy in Upper Tract Urothelial Cancer. J Clin Oncol 35(8):816-817, 2017. e-Pub 2017. PMID: 28165904.
- Bilen MA, Hess KR, Campbell MT,, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget 7(52):86280-86289, 2016. e-Pub 2016. PMID: 27861143.
- Matrana MR, Bathala T, Campbell MT,, Duran C, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Tannir NM. Outcomes of Unselected Patients with Metastatic Clear-Cell Renal Cell Carcinoma Treated with Front-Line Pazopanib Therapy Followed by Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors (VEGFR-TKI) or Mammalian Target of Rapamycin Inhibitors (mTORi): A Single Institution Experience. BJU Int 118(2):264-71, 2016. e-Pub 2015. PMID: 26573089.
- Campbell MT,, Jonasch E. Treatment of Relapsed Germ Cell Tumors: Time For Something New?. J Oncol Pract 12(5):449-50, 2016. PMID: 27170695.
- Siefker-Radtke AO, Campbell MT,, Munsell MF, Harris DR, Carolla RL, Pagliaro LC. Front-line treatment with gemcitabine, paclitaxel and doxorubicin for patients with unresectable or metastatic urothelial cancer and poor renal function: Final results from a phase II study. Urology 89:83-9, 2016. e-Pub 2015. PMID: 26723185.
- Campbell MT,, Siefker-Radtke AO, Gao J. The state of Immune Check Point Inhibition in Urothelial Carcinoma: current Evidence and Future Areas of Exploration. Cancer J 22(2):96-100, 2016. PMID: 27111904.
- Campbell MT, Millikan RE, Altinmakas E, Xiao L, Wen SJ, Siefker-Radtke AO, Aparicio A, Corn PG, Tannir NM. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma. Clin Genitourin Cancer 13(3):218-24, 2015. e-Pub 2014. PMID: 25465491.
- Campbell SR, Campbell MT, Shah C, et al.. Educational conference scheduling, patient discharge time, and resident satisfaction. Journal of Graduate Medical Education 6(3):574-576, 2014.
- Zhang H, Hile KL, Asanuma H, Vanderbrink B, Franke EI, Campbell MT, Meldrum KK. IL-18 mediates proapoptotic signaling in renal tubular cells through a Fas ligand-dependent mechanism. Am J Physiol Renal Physiol 301(1):F171-8, 2011. e-Pub 2011. PMID: 21511702.
- Campbell MT, Hile KL, Zhang H, Asanuma H, Vanderbrink BA, Rink RR, Meldrum KK. Toll-like receptor 4: a novel signaling pathway during renal fibrogenesis. J Surg Res 168(1):e61-9, 2011. e-Pub 2009. PMID: 20089260.
- Asanuma H, Vanderbrink BA, Campbell MT, Hile KL, Zhang H, Meldrum DR, Meldrum KK. Arterially delivered mesenchymal stem cells prevent obstruction-induced renal fibrosis. J Surg Res 168(1):e51-9, 2011. e-Pub 2010. PMID: 20850784.
- Bani-Hani AH, Leslie JA, Asanuma H, Dinarello CA, Campbell MT, Meldrum DR, Zhang H, Hile K, Meldrum KK. IL-18 neutralization ameliorates obstruction-induced epithelial-mesenchymal transition and renal fibrosis. Kidney Int 76(5):500-11, 2009. e-Pub 2009. PMID: 19536084.
- Campbell MT, Dagher P, Hile KL, Zhang H, Meldrum DR, Rink RC, Meldrum KK. Tumor necrosis factor-alpha induces intrinsic apoptotic signaling during renal obstruction through truncated bid activation. J Urol 180(6):2694-700, 2008. e-Pub 2008. PMID: 18951565.
- Bani-Hani AH, Campbell MT, Meldrum DR, Meldrum KK. Cytokines in epithelial-mesenchymal transition: a new insight into obstructive nephropathy. J Urol 180(2):461-8, 2008. e-Pub 2008. PMID: 18550128.
- Metcalfe PD, Leslie JA, Campbell MT, Meldrum DR, Hile KL, Meldrum KK. Testosterone exacerbates obstructive renal injury by stimulating TNF-alpha production and increasing proapoptotic and profibrotic signaling. Am J Physiol Endocrinol Metab 294(2):E435-43, 2008. e-Pub 2007. PMID: 18073317.
- Choueiri T, Motzer R, Campbell MT,, Alekseev B, Uemura M, Kollmansberger C, Gravis G, Bjarnson G, Gurney H, Jin Soo C, Haanen J, Rini B, Larken J, Schmidinger M, Nole F, Chudnovsky A, Huang B, Hariharan S, di Pietro A, Albiges L.. JAVELIN Renal 101: randomized phase 3 trial of avelumab + axitinib (A + Ax) vs sunitinib (S) as first-line (1L) treatment of advanced renal cell carcinoma (aRCC).
- Metcalfe MJ, Ferguson JE, Li R, Xiao L, Guo CC, Czerniak BA, Siefker-Radtke A, Pretzsch SM, Navai N, McConkey DJ, Kamat AM, Campbell MT,, Dinney C. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Eur Urol Focus. e-Pub 2017. PMID: 28753816.
- Msaouel P, Bilen MA, Zhang M, Campbell MT,, Wang J, Tu SM. Recent developments in the management of germ cell tumors. Curr Opin Oncol. e-Pub 2017. PMID: 28151756.
Invited Articles
- Campbell MT, Jonasch E. Updates in the Systemic Treatment of Patients with Metastatic Renal Cell Carcinoma. e-Pub 2016.
Manuals, Teaching Aids, Other Teaching Publications
- Campbell MT, Choi SL, Corn P, Jonasch E, Karam J, Matin S, Ng CS, Nguyen Q, Tannir N, Wood C. Renal Cell Carcinoma treatment. The University of Texas MD Anderson Cancer Center: Houston, 2015.
Other Articles
- Brophy Marcus, Mary Guys, Why Aren't You Checking Your Balls For Testicular Cancer?. Men's Health Magazine, 2018.
Editorials
- Campbell, MT, Kamat, A. New Drug Development in Urothelial Cancer: An Explosion of Riches?. ASCO Daily News, 2017.
- Campbell MT. Metastatic Renal Cell Carcinoma: Current Therapies and Mechanisms of Resistance. ASCO Daily News, 2016.
Abstracts
- Laccetti, Campbell MT,, Economides, Gao, Jonasch, Corn, Zurita, Tannir, Msaouel, and Shah. Combination anti-angiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Genitourinary Cancer Symposium 2019 - Journal of Clinical Oncology 37(7S), 2019.
- Shah A, Lemke E, Gao J, Chandramohan A, Campbell MT,, Zurita AJ, Xiao L, Wang J, Corn PG, Jonasch E, Sharma P, Tannir NM. Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Genitourinary Cancer Symposium 2019 - Journal of Clinical Oncology 37(7s), 2019.
- Campbell, MT. Comparing cabozantinib (C) treatment for a cohort of patients with metastatic clear cell (ccRCC) and variant histology renal cell carcinoma (vhRCC): a retrospective study. Genitourinary Cancer Symposium 2018 - Journal of Clinical Oncology 36(6S), 2018.
- Campbell MT, Bilen Mehmet A, Duran C, Altinmakas E, Lim ZD, Jonasch E, Tannir N. Cabozantinib for the treatment of patients with metastatic variant histology renal cell carcinoma(vhRCC): a retrospective study. ESMO Congress - Madrid, Spain, 2017.
- Campbell MT,Matin SF, Slack B, Sun JJ, Chen H, NG Tang D, Zhang L, Rao P, Sharma P. Thermal ablation induces local and systemic immune changes in patients with metastatic renal cell carcinoma. Annual ASCO (American Society of Clinical Oncology) Genitourinary Cancers Symposium, 2017.
- Campbell MT, Bilen MA, Duran C, Altinmakas E, Lim ZD, Jonasch E, Tannir NM. Cabozantinib for the treatment of patients with metastatic variant histology renal cell carcinoma(vhRCC): a retrospective study. Genitourinary Cancer Symposium 2017 - Journal of Clinical Oncology 35(suppl 6S; abstract 478), 2017.
- Gao JJ, Karam JA, Wood CG, Matin S, Ahrar K, Jonasch E, Tannir N, Campbell MT,Ng C, Slack R, Rao P, Allison JP, Blando JM, Vence LM, Basu S, Zhao H, Chen T, Chen H, Sharma P. Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma. AACR (American Association for Cancer Research), 2017.
- Nieto Y, Tu SM, Campbell MT,Bassett R, Tannir N, Ward J, Hofstetter W, Jones RB, Andersson BS, Gulbis A, Ledesma C, Timmons M, Trapp M, Champlin R, Pagliaro L. Infusional Gemcitabine + Docetaxel/melphalan/Carboplatin (GemDMC) + Bevacizumab (BEV) is an Effective High-Dose Chemotherapy (HDC) Regimen for Refractory of Pro-Risk Relapsed Germ-Cell Tumors (GCT). ASCO (American Society of Clinical Oncology), 2017.
- Campbell MT,Matin SF, Slack B, Sun JJ, Chen H, NG Tang D, Zhang L, Rao P, Sharma P. Ablative Therapy to Induce local and systemic changes in patients with metastatic renal cell carcinoma. Genitourinary Cancer Symposium 2017 - Journal of Clinical Oncology, 2017.
- Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Rao P, Zhang M, General R, Cauley DH, Lin SH, Pisters LL, Tu SM. Intratumoral hterogeneity and chemo-resistance in nonseminomatous germ cell tumor of the testis. J Clin Oncol, 2016.
- Campbell MTMcConkey DJ, Matina SF, Kamat AM, Dinney CP, Wang J, Gao JJ, Siefker-Radtke AO. The hotspot mutational landscape of upper tract and bladder urothelial cancers and correlation to survival. Genitourinary Cancer Symposium 2016 - Journal of Clinical Oncology 34(suppl 2S; abstr 466), 2016. e-Pub 2016.
- Campbell MT, Shah AY, Nautiyal KD, Hashemi N, Corn PG, Pagliaro LC, Jonasch E, Tannir NM. Association of chronic co-morbidities with long term survival with metastatic renal cell carcinoma (mRCC). Genitourinary Cancer Symposium 2015 - Journal of Clinical Oncology 33(suppl 7), 2015.
- Campbell MT, Shah AY, Hashemi N, Nautiyal KD, Corn PG, Pagliaro LC, Jonasch E, Tannir NM.. Long-term survivorship in patients (pts) with metastatic renal cell cancer (mRCC): A retrospective study from the MD Anderson Cancer Center (MDACC). Genitourinary Cancer Symposium 2015 - Journal of Clinical Oncology 33(suppl 7):suppl 7, 2015.
- Shah AY, Campbell MT,Nautiyal KD, Hashemi Neda, Matin SF, Vaporciyan AA, Rhines LD, Moon B, Lewis VO, Lin PP, Prabhu SS, Rao G, Corn PG, Pagliaro LC, Mehran RJ, Wood CJ, Jonasch E, Tannir NM. Long-term survivorship in patients with metastatic renal cell cancer (mRCC) managed with metastasectomy: A retrospective study from the MD Anderson Cancer Center (MDACC). Genitourinary Cancer Symposium 2015 - Journal of Clinical Oncology 33(suppl 7), 2015.
- Campbell MT, Millikan R., Emre A, Xiao L, Tannir NM. Phase I trial of sunitinib (S) and temsirolimus (T) in metastatic renal cell carcinoma (mRCC). Genitourinary Cancer Symposium 2014 - Journal of Clinical Oncology 32(suppl 4), 2014.
- Campbell MT, Jung J, Philips S, Mohammadi Y, Carr KA, Davis TL, Li L, Sweeney CJ, Skaar TC. Germline single nucleotide polymorphism (SNP) predictors of progression free survival and overall survival in advanced prostate cancer patients treated with androgen deprivation therapy (ADT). Poster presented at: Genitourinary American Society of Clinical Oncology Meeting; Orlando, FL, 2011.
- Campbell MT, Hile K, Zhang H, Asanuma H, Rink R, Meldrum KK. Toll-like receptor 4: a novel signaling pathway during renal fibrogenesis. Poster presented at: American Academy of Pediatrics National Meeting; Boston, MA, 2008.
Book Chapters
- Campbell, MT,Jonasch E, Wood CG, Tannir NM. Renal Cell Carcinoma. In: The MD Anderson Manual of Medical Oncology. Third Edition, 2016.
- Campbell MT,, Sharma A, Goswami S, Sharma P. Tumor Immunotherapy. In: Clinical Immunology: Principles and Practice, 5th Edition, 2016.
- Sharma, A, Campbell, MT, Yee, C, Goswami, S, Sharma, P. Immunotherapy of Cancer. In: Clinical Immunology.
Grant & Contract Support
| Title: | Adaptive antitumor immune activation by molecularly target photothermal ablation |
| Funding Source: | UTMDACC |
| Role: | Collaborator |
| Title: | Conquer Cancer Foundation ASCO Young Investigator Award – Enhancing therapeutic efficacy in metastatic renal cell carcinoma by combining immune check point blockade with cryoablation |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | Principal Investigator |